BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 1359154)

  • 1. Phase I trial of Taxotere: five-day schedule.
    Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
    J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
    Tomiak E; Piccart MJ; Kerger J; Lips S; Awada A; de Valeriola D; Ravoet C; Lossignol D; Sculier JP; Auzannet V
    J Clin Oncol; 1994 Jul; 12(7):1458-67. PubMed ID: 7912725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
    Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
    J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
    Extra JM; Rousseau F; Bruno R; Clavel M; Le Bail N; Marty M
    Cancer Res; 1993 Mar; 53(5):1037-42. PubMed ID: 8094996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
    Bissett D; Setanoians A; Cassidy J; Graham MA; Chadwick GA; Wilson P; Auzannet V; Le Bail N; Kaye SB; Kerr DJ
    Cancer Res; 1993 Feb; 53(3):523-7. PubMed ID: 8093854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
    Gelmon KA; Latreille J; Tolcher A; GĂ©nier L; Fisher B; Forand D; D'Aloisio S; Vernillet L; Daigneault L; Lebecq A; Besenval M; Eisenhauer E
    J Clin Oncol; 2000 Dec; 18(24):4098-108. PubMed ID: 11118471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Soh LT; Ajani JA; Bready B; Soo E; Sugarman S; Patt Y; Abbruzzese JL; Levin B
    Ann Oncol; 1994 May; 5(5):468-70. PubMed ID: 7915537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
    J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
    Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.